Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer
Authors
Keywords
Docetaxel, Anaplastic Lymphoma Kinase, National Comprehensive Cancer Network, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Anaplastic Lymphoma Kinase Inhibitor
Journal
DRUGS
Volume 76, Issue 9, Pages 969-978
Publisher
Springer Nature
Online
2016-05-17
DOI
10.1007/s40265-016-0589-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
- (2015) B Homet Moreno et al. BRITISH JOURNAL OF CANCER
- Nivolumab: A Review in Advanced Squamous Non-Small Cell Lung Cancer
- (2015) Gillian M. Keating DRUGS
- Nivolumab: A Review in Advanced Melanoma
- (2015) Lesley J. Scott DRUGS
- 521 Phase II studies of Nivolumab in patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC)
- (2015) H. Sakai et al. EUROPEAN JOURNAL OF CANCER
- 3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs)
- (2015) L. Horn et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab: targeting PD-1 to bolster antitumor immunity
- (2015) Julie R Brahmer et al. Future Oncology
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
- (2015) Keith M. Kerr et al. Journal of Thoracic Oncology
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience
- (2015) David Berman et al. PHARMACOLOGY & THERAPEUTICS
- Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer
- (2015) Nathan A. Pennell SEMINARS IN ONCOLOGY
- Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic
- (2015) Mark A. Socinski SEMINARS IN ONCOLOGY
- Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer
- (2015) Edward B. Garon SEMINARS IN ONCOLOGY
- Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer
- (2015) Therese Phillips et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
- (2015) Luisa Carbognin et al. PLoS One
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
- (2014) Martin Reck et al. LANCET ONCOLOGY
- In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
- (2014) C. Wang et al. Cancer Immunology Research
- Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
- (2013) C. Zielinski et al. ANNALS OF ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now